Compare WBX & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WBX | PGEN |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | Spain | United States |
| Employees | 1108 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0M | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | WBX | PGEN |
|---|---|---|
| Price | $2.94 | $4.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.75 | ★ $8.33 |
| AVG Volume (30 Days) | 17.7K | ★ 5.1M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $60.77 | $1,115.92 |
| Revenue Next Year | $49.46 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $1.12 |
| 52 Week High | $7.83 | $5.47 |
| Indicator | WBX | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 57.79 |
| Support Level | $2.30 | $4.02 |
| Resistance Level | $3.21 | $4.44 |
| Average True Range (ATR) | 0.22 | 0.31 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 39.71 | 87.04 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.